BioSpace reviews whose wallets got thicker in the biopharma industry, from largest to smallest, during the Nov. 11-17 period

San Francisco-based Olema Oncology secured $54 million in an oversubscribed Series B financing round to support the development of the company’s lead breast cancer treatment as well as expand ongoing research and development programs.

Morphic Therapeutic has completed a $80 million Series B financing to fund the biotechnology company’s two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic.

ReViral announced the completion of a Series B financing worth $55 million, jointly led by New Leaf Venture Partners and Novo Ventures, with new investors Perceptive Advisors.

April 20, 2016By Mark Terry, BioSpace.com Breaking News Staff   South San Francisco-based Second Genome announced today that it had closed on a Series B investment round with $42.6 million. It was co-led by Pfizer Venture Investments and Roche Venture Fund. They were joined by new investors, Digitalis Ventures, Adveq, LifeForce Capital, MBL Venture Capital, […]

April 19, 2016By Mark Terry, BioSpace.com Breaking News Staff   DalCor Pharmaceuticals, which maintains offices in San Mateo, Calif., Switzerland, the UK and Montreal, Canada, announced today that it had wrapped up a private financing round valued at $150 million. Late in 2015, the company closed on a $50 million Series A round, and completed […]

SAN DIEGO, April 4, 2016 /PRNewswire/ — Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, announced today that the company has completed an offering of Series B Preferred Stock, raising in excess of $220 million. HLI previously raised $80 million in its Series A offering which closed in Summer 2014. “The closing of our Series […]